Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
Older
Apr 26, 2016
Neuren Shareholder Update
Apr 26, 2016
Results of Phase 2 trial in moderate to severe TBI
Apr 22, 2016
Trading Halt
Apr 18, 2016
Appendix 4G
Apr 18, 2016
Annual Report to shareholders
Apr 07, 2016
First subject commences Neuren's Rett syndrome Phase 2 trial
Feb 25, 2016
Neuren reports 2015 full-year financial results
Feb 25, 2016
Appendix 4E and Financial Report 31 December 2015
Jan 29, 2016
Appendix 4C - quarterly
Jan 11, 2016
Neuren Investor Presentation, 11 January 2016
Previous
1
2
3
4
Next
